Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2006-02-02
2009-08-18
Szperka, Michael (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C514S002600, C530S330000
Reexamination Certificate
active
07576174
ABSTRACT:
The invention includes a method of reducing urea concentration in a subject's serum. Such a method comprises administering to the subject (e.g., a mammal such as a human) a composition comprising an oligopeptide (or oligopeptides) having activity in reducing urea concentration in the subject's serum as determined by a mouse renal reperfusion test, wherein the oligopeptide comprises the sequence AQG or MTRV (SEQ ID NO:1), AQGV (SEQ ID NO:2) or LAGV (SEQ ID NO:4).
REFERENCES:
patent: 4977244 (1990-12-01), Muchmore et al.
patent: 5380668 (1995-01-01), Herron
patent: 5677275 (1997-10-01), Lunardi-Iskandar et al.
patent: 5851997 (1998-12-01), Harris
patent: 5854004 (1998-12-01), Czernilofsky et al.
patent: 5877148 (1999-03-01), Lunardi-Iskandar et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5968513 (1999-10-01), Gallo et al.
patent: 5997871 (1999-12-01), Gallo et al.
patent: 6319504 (2001-11-01), Gallo et al.
patent: 6361992 (2002-03-01), Szkudlinski et al.
patent: 6489296 (2002-12-01), Grinnell et al.
patent: 6583109 (2003-06-01), Gallo et al.
patent: 6596688 (2003-07-01), Gallo et al.
patent: 6620416 (2003-09-01), Gallo et al.
patent: 6727227 (2004-04-01), Khavinson
patent: 2002/0041871 (2002-04-01), Brudnak
patent: 2002/0064501 (2002-05-01), Khan et al.
patent: 2003/0049273 (2003-03-01), Gallo et al.
patent: 2003/0113733 (2003-06-01), Khan et al.
patent: 2003/0119720 (2003-06-01), Khan et al.
patent: 2003/0166556 (2003-09-01), Khan et al.
patent: 2003/0186244 (2003-10-01), Margus et al.
patent: 2003/0215434 (2003-11-01), Khan et al.
patent: 2003/0219425 (2003-11-01), Khan et al.
patent: 2003/0220257 (2003-11-01), Benner et al.
patent: 2003/0220258 (2003-11-01), Benner et al.
patent: 2003/0220259 (2003-11-01), Benner et al.
patent: 2003/0220260 (2003-11-01), Khan et al.
patent: 2003/0220261 (2003-11-01), Khan et al.
patent: 2003/0224995 (2003-12-01), Khan et al.
patent: 2004/0013661 (2004-01-01), Wensvoort et al.
patent: 3715662 (1987-11-01), None
patent: 19953339 (2001-05-01), None
patent: 1 138 692 (2001-10-01), None
patent: 1 300 418 (2003-04-01), None
patent: 2 706 772 (1994-12-01), None
patent: 96/04008 (1996-02-01), None
patent: 97/49373 (1997-12-01), None
patent: 97/49418 (1997-12-01), None
patent: 97/49432 (1997-12-01), None
patent: WO 97/49721 (1997-12-01), None
patent: WO 98/35691 (1998-08-01), None
patent: WO 99/59617 (1999-11-01), None
patent: WO 01/10907 (2001-02-01), None
patent: WO 01/11048 (2001-02-01), None
patent: WO 01/29067 (2001-04-01), None
patent: WO 01/68113 (2001-09-01), None
patent: WO 01/72831 (2001-10-01), None
patent: WO 02/085117 (2002-10-01), None
patent: WO 03/029292 (2003-04-01), None
Albini, A., et al., “Old drugs as novel angiogenesis inhibitors: Preclinical studies with NAC, hCG, EGCG and somatostatin,” 17 Clinical & Experimental Metastasis 739 (1999).
Blackwell, Timothy S., et al., “The Role of Nuclear Factor-kB in Cytokine Gene Regulation,” 17 Am. J. Respir. Cell Mol. Biol. 3-9 (1997).
Christman et al., Nuclear factor kappaB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy, Intens Care Med, 1998, pp. 1131-1138, vol. 24.
Connelly et al., Biphasic Regulation of NF-kB Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-3881, 166, The American Association of Immunologists, USA.
Friedlander, Tackling anthrax, Nature, Nov. 8, 2001, pp. 160-161, vol. 414.
Iskandar et al., “Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease”, Nature Medicine, Apr. 1998, vol. 4, No. 4, pp. 428-434.
Jyonouchi et al., Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression, J Neuroim., 2001, pp. 170-179, vol. 120.
Kachra et al., “Low Molecular Weight Components but Not Dimeric HCG Inhibit Growth and Down-Regulate AP-1 Transcription Factor in Kaposi's Sarcoma Cells,” Endocrinology, 1997, pp. 4038-4041, vol. 138, No. 9.
Kanungo et al., Advanced Maturation of Heteropneustes Fossilis (Bloch) by Oral Administration of Human Chorionic Gonadotropin, J. Adv. Zool., 1999, pp. 1-5, vol. 20.
Keller, S., et al., “Human Chorionic Gonadotropin (hCG) Is a Potent Angiogenic Factor for Uterine Endothelial Cells in Vitro,” 20(5-6) Placenta, p. A37 (Jul. 1999).
Khan, Nisar A., et al., “Inhibition of Diabetes in NOD Mice by Human Pregnancy Factor,” 62(12) Human Immunology 1315-1323 (Dec. 2001).
Khan, Nisar A., et al., “Inhibition of Septic Shock in Mice by an Oligopeptide From the β-Chain of Human Chorionic Gonadotrophin Hormone,” 63(1) Human Immunology 1-7 (Jan. 2002).
Lang et al., “Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin”, AIDS 1997, vol. 11, No. 11, pp. 1333-1340.
Medzhitov, Toll-like Receptors and Innate Immunity, Nature Reviews/Immunology, Nov. 2001, pp. 135-145, vol. 1.
Muchmore et al., Immunoregulatory Properties of Fractions from Human Pregnancy Urine: Evidence that Human Chorionic Gonadotropin is not Responsible, The Journal of Immunology, Mar. 1997, pp. 881-886, vol. 118, No. 3.
Muchmore et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained from Human Pregnancy Urine, Journal of Experimental Medicine, Dec. 1984, pp. 1672-1685, vol. 160.
Patil, A., et al., “The Study of the Effect of Human Chorionic Gonadotrophic (HCG) Hormone on the Survival of Adrenal Medulla Transplant in Brain. Preliminary Study,” 87 Acta Neurochir (WIEN) 76-78 (1987).
Rohrig et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) on Plasmodium falciparum in vitro, Zentralblatt Bakt, 1999, pp. 89-99, vol. 289.
Slater, Lewis M., et al., “Decreased Mortality of Murine Graft-VersUS -Host Disease by Human Chorionic gonadotropin,”23(1) Transplantation 103-104 (Jan. 1977).
Tak et al., NF-kappaβ: a key role in inflammtory diseases, J Clin Invest., 2001, pp. 7-11, vol. 107.
Tan et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, vol. 55.
Tovey et al., Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity, J. Interferon Cytokine Res., 1999, pp. 911-921, vol. 19.
Wulczyn, F. Gregory, et al., “The NF-kB/Rel and IkB gene families: mediators of immune response and inflammation,” 74(12) J. Mol. Med. 749-769 (1996).
Yamamoto, Y., et al., “Role of the NF-kB Pathway in the Pathogenesis of Human Disease States,” 1(3) Current Molecular Medicine 287-296 (Jul. 2001).
Ivanov et al., “Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool,” Biopolymers, 1997, pp. 171-188, vol. 39.
Khavinson et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.
Khavinson et al., “Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People,” Bulletin of Experimental Biology and Medicine, Oct. 2002, pp. 389-392, vol. 134, No. 4.
Khavinson et al., “Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects,” Bulletin of Experimental Biology and Medicine, Jan. 2004, pp. 78-81, vol. 137, No. 1.
Khavinson et al., “Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells,” Bulletin of Experimental Biology and Medicine, Jun. 2003, pp. 590-592, vol. 135, No. 6.
Khavinson et al., “Inductive Activity of Retinal Peptides,” Bulletin of Experimental Biology and Medicine, Nov. 2002, pp. 482-484, vol. 134, No. 5.
Khavinson et al., “Mechanisms Underlying Geroprotective Effects of Peptides,” Bulletin of Experimental Biology and Medicine, Jan. 2002, pp. 1-5, vol. 133, No. 1.
Khavinson et al., “Peptide P
Benner Robbert
Khan Nisar Ahmed
Biotempt B.V.
Kim Yunsoo
Szperka Michael
TraskBritt
LandOfFree
Compositions capable of reducing elevated blood urea... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions capable of reducing elevated blood urea..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions capable of reducing elevated blood urea... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4073921